Clinical Trial HALF

Masaryk University is the sponsor of a multicenter prospective phase II clinical trial called HALF, which evaluates the efficacy and safety of thyrosine kinase withdrawal nationwide after a previous two-stage dose reduction in patients with chronic myeloid leukemia in deep molecular remission. This 5-year clinical trial will take place in 8 centres, with 150 patients followed for 36 months. The protocol’s idea and design was initiated by the Department of Internal Hematology and Oncology, University Hospital Brno, and the study is being carried out in cooperation with LRI CZECRIN.